Oragenics, Inc. Announces Conversion of Preferred Shares and Elimination of Liquidation Preference
December 16, 2024 08:09 ET
|
Oragenics
Oragenics, Inc. Announces Conversion of Preferred Shares and Elimination of Liquidation Preference
Oragenics, Inc. to Present at The Centurion One Capital 2nd Annual Bahamas Summit
October 18, 2024 08:30 ET
|
Oragenics
SARASOTA, Fla., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Oragenics Inc. (NYSE American: OGEN), a company focused on developing new treatments for brain-related health conditions, announced it will be...
Oragenics, Inc. Updates Shareholders on Concussion Drug Progress and Phase II Trial Preparation
October 09, 2024 07:30 ET
|
Oragenics
SARASOTA, Fla., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biopharmaceutical company committed to developing novel therapies for neurological disorders, today...
Oragenics Inc. Successfully Completes Key FDA-Recognized Study for ONP-002
October 08, 2024 08:45 ET
|
Oragenics
SARASOTA, Fla., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Oragenics Inc. (NYSE American: OGEN), a company focused on developing new treatments for brain-related health conditions, has completed a key study...
Oragenics, Inc. Announces Closing of Public Offering
September 05, 2024 16:30 ET
|
Oragenics
SARASOTA, Fla., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological...
Oragenics, Inc. Announces Pricing of Public Offering
September 04, 2024 08:36 ET
|
Oragenics
Oragenics, Inc. Announces Pricing of Public Offering
Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients
August 21, 2024 08:45 ET
|
Oragenics
• Falls and car accidents lead incidence of concussions in emergency departments • Spray-dried drug formulation allows for easy delivery to patients • No pharmaceutical treatment is available for...
Oragenics, Inc. Provides Update on its Drug Intended to Treat Concussion and Non-Compliance with NYSE American Continued Listing Standards
August 16, 2024 16:30 ET
|
Oragenics
SARASOTA, Fla., Aug. 16, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN) ("the Company"), a company focused on developing unique, intranasal pharmaceuticals for the treatment of...
Oragenics Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range
August 14, 2024 08:30 ET
|
Oragenics
• ONP-002 stability eliminates need for cumbersome cold storage• No FDA-approved pharmaceutical treatment available for concussion SARASOTA, Fla., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Oragenics,...
Oragenics, Inc. Announces Concussion Drug Successfully Completes FDA-Required Genotoxicity Study
August 12, 2024 08:30 ET
|
Oragenics
– ONP-002 showed no cancer-causing DNA damage – Phase II clinical trial being planned SARASOTA, Fla., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on...